ArticleRadiology. Imaging cancer2025
Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma and Associated Prognosis Using Contrast-enhanced US and Clinical Features.
Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04682886 (Research on Key Techniques for Intelligent Diagnosis and Ablation Decision-making of Liver Cancer and Evolution by Contrast-enhanced Ultrasound), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on Key Techniques for Intelligent Diagnosis and Ablation Decision-making of Liver Cancer and Evolution by Contrast-enhanced Ultrasound
Who cites it
5 citing papers in PubMed.
- Temporal Differentiation of Nonperipheral Washout Refines Prognostic Stratification in HCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Contrast-enhanced ultrasound and clinical features for preoperative prediction of GPC-3 expression in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- CRAFITY and PALBI Define a Machine Learning-Supported Prognostic Framework in Hepatocellular Carcinoma-Data from an Eastern European Cohort with Low Macrotrabecular-Massive Prevalence.Diseases (Basel, Switzerland) · 2026Article
- A Non-Invasive Integrated Model for Accurate Preoperative Identification of the Aggressive Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Macrotrabecular-Massive Subtype Is Associated with a High Risk of the Recurrence of Hepatocellular Carcinoma.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To develop a combined contrast-enhanced US (CEUS) clinical model for the prediction of macrotrabecular-massive hepatocellular carcinoma (MTM HCC) and evaluate its diagnostic and prognostic values. Materials and Methods This secondary analysis of a prospective multicenter study (ClinicalTrials.gov: NCT04682886) included participants from three independent cohorts who underwent CEUS and surgical resection for HCC between January 2017 and December 2022. Two radiologists independently reviewed CEUS data, and the interreader agreement was evaluated. Logistic regression was performed using the training cohort to determine the predictors associated with MTM HCC, while the validation cohort was used to evaluate the diagnostic and prognostic values of the predictors. Results A total of 387 participants (mean age, 55.09 years ± 10.33 [SD]; 342 male) were included. Four clinical and CEUS features were associated with MTM HCC: early washout (before 60 seconds) (odds ratio [OR]: 8.82 [95% CI: 4.22, 18.64],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.